Royal London Asset Management Ltd. Has $86.32 Million Position in Abbott Laboratories (NYSE:ABT)

Royal London Asset Management Ltd. boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 763,170 shares of the healthcare product maker's stock after buying an additional 18,272 shares during the quarter. Royal London Asset Management Ltd.'s holdings in Abbott Laboratories were worth $86,322,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ABT. United Bank boosted its stake in shares of Abbott Laboratories by 1.8% in the 3rd quarter. United Bank now owns 27,284 shares of the healthcare product maker's stock valued at $3,111,000 after purchasing an additional 488 shares during the last quarter. BIP Wealth LLC grew its holdings in Abbott Laboratories by 50.1% during the 3rd quarter. BIP Wealth LLC now owns 3,128 shares of the healthcare product maker's stock worth $357,000 after acquiring an additional 1,044 shares during the period. Avior Wealth Management LLC boosted its position in shares of Abbott Laboratories by 38.0% in the 3rd quarter. Avior Wealth Management LLC now owns 42,700 shares of the healthcare product maker's stock worth $4,868,000 after purchasing an additional 11,768 shares during the last quarter. Prospera Private Wealth LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $211,000. Finally, Strategy Asset Managers LLC increased its holdings in Abbott Laboratories by 51.0% in the third quarter. Strategy Asset Managers LLC now owns 9,392 shares of the healthcare product maker's stock valued at $1,071,000 after purchasing an additional 3,173 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Remove Ads

Abbott Laboratories Stock Up 0.8 %

Shares of Abbott Laboratories stock traded up $0.97 on Monday, reaching $127.31. 5,283,007 shares of the company were exchanged, compared to its average volume of 5,481,777. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average of $128.51 and a 200 day moving average of $119.94. The company has a market capitalization of $220.79 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.52 and a beta of 0.70.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter last year, the firm posted $1.19 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.85%. Abbott Laboratories's dividend payout ratio is currently 30.85%.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABT. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. Citigroup upped their price objective on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an "outperform" rating and set a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. StockNews.com lowered Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus boosted their price objective on Abbott Laboratories from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $137.94.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares of the company's stock, valued at $9,625,404.96. This represents a 55.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the sale, the executive vice president now owns 74,381 shares of the company's stock, valued at $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,449 shares of company stock valued at $15,463,316. 1.10% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.